Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : -Myers Granted Right to Buy Promedior

08/31/2015 | 09:25am US/Eastern

Bristol-Myers Squibb Co. said Monday that it has been granted the exclusive right to buy privately held Promedior Inc. and its experimental fibrosis treatment for up to $1.25 billion.

Under the terms of the agreement, Bristol-Myers will pay $150 million in cash up front for the right to buy Promedior. Bristol-Myers can exercise that right after Promedior completes either of two phase-two trials for the treatment PRM-151.

Promedior expects to begin clinical trials of the treatment for idiopathic pulmonary fibrosis and myelofibrosis patients in the coming weeks. PRM-151 has been granted fast-track designation and orphan designation.

Fibrosis is associated with several rare diseases and illnesses such as age-related macular degeneration and solid tumors. Fibrosis occurs when healthy tissue is replaced with scar tissue, which can compromise function and lead to organ failure.

Bristol-Myers said the drug will complement its early-stage fibrosis portfolio. The company last year signed an option agreement to buy Galecto Biotech AB, a company with an inhaled inhibitor for the treatment of idiopathic pulmonary fibrosis.

Write to Chelsey Dulaney at Chelsey.Dulaney@wsj.com

React to this article
Latest news on BRISTOL-MYERS SQUIBB CO
09:25aDJBRISTOL MYERS SQUIBB : -Myers Granted Right to Buy Promedior
09:23a BRISTOL MYERS SQUIBB : -Myers buys rights to fibrosis drug
09:17aDJBRISTOL MYERS SQUIBB : -Myers Granted Right to Buy Promedior for up to $1.25 Bil..
08:31a BRISTOL MYERS SQUIBB : Enters Agreement Providing Exclusive Right to Acquire Pro..
03:29a BRISTOL MYERS SQUIBB : Allied Minds Reports Half-Yearly Results
03:29a BRISTOL MYERS SQUIBB : Allied-Bristol Life Sciences Licenses Platform Technology..
03:22a BRISTOL MYERS SQUIBB : and Pfizer to Participate at the ESC Congress 2015
08/30 BRISTOL MYERS SQUIBB : -Myers, QIMR Collaborate To Discover Novel Immuno-Oncolog..
08/30 BRISTOL MYERS SQUIBB : and QIMR Berghofer Medical Research Institute Announce Wo..
08/28 Syngene to spend $100 million on new plant at mangalore sez
Advertisement
Chart
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Income Statement Evolution
More Financials